Patents by Inventor Harish Govindaraja Setty CHINNARI
Harish Govindaraja Setty CHINNARI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240075014Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.Type: ApplicationFiled: November 6, 2023Publication date: March 7, 2024Applicant: SLAYBACK PHARMA LLCInventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
-
Patent number: 11844784Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.Type: GrantFiled: June 2, 2023Date of Patent: December 19, 2023Assignee: SLAYBACK PHARMA LLCInventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
-
Publication number: 20230381282Abstract: Stable injectable compositions comprising glucagon or a pharmaceutically acceptable salt, solvate, or hydrate thereof are disclosed. Preferably, the composition is provided in a sealed container, e.g., an ampoule, a vial, a pre-filled syringe or an auto-injector. Further, stable injectable solutions are disclosed, which comprise glucagon or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and which are suitable for subcutaneous, intravenous or intramuscular administration. Methods for manufacturing stable injectable solutions of glucagon are also disclosed.Type: ApplicationFiled: May 25, 2023Publication date: November 30, 2023Applicant: Slayback Pharma LLCInventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
-
Patent number: 11786512Abstract: The present invention relates to stable pharmaceutical compositions of dihydroergotamine mesylate or other pharmaceutically acceptable salts thereof and methods for preparing the compositions particularly for the treatment of migraine headaches. The invention further relates to stable injectable composition comprising dihydroergotamine or its pharmaceutically acceptable salts thereof, wherein the composition has a pH from about 5.0 to about 6.0. Further, the present invention relates to a method of treating migraine comprising providing a stable pharmaceutical composition for parenteral administration comprising dihydroergotamine mesylate, wherein the pH of the composition ranges from 5.0 to 6.0 and, wherein the composition comprises no greater than 3% of total impurities as determined by HPLC.Type: GrantFiled: September 22, 2020Date of Patent: October 17, 2023Assignee: SLAYBACK PHARMA LLCInventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Jagdish Lotan Lohar
-
Publication number: 20230310384Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.Type: ApplicationFiled: June 2, 2023Publication date: October 5, 2023Applicant: SLAYBACK PHARMA LLCInventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
-
Patent number: 11707450Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine or its pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.Type: GrantFiled: July 29, 2022Date of Patent: July 25, 2023Assignee: SLAYBACK PHARMA LLCInventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
-
Publication number: 20210085657Abstract: The present invention relates to stable pharmaceutical compositions of dihydroergotamine mesylate or other pharmaceutically acceptable salts thereof and methods for preparing the compositions particularly for the treatment of migraine headaches. The invention further relates to stable injectable composition comprising dihydroergotamine or its pharmaceutically acceptable salts thereof, wherein the composition has a pH from about 5.0 to about 6.0. Further, the present invention relates to a method of treating migraine comprising providing a stable pharmaceutical composition for parenteral administration comprising dihydroergotamine mesylate, wherein the pH of the composition ranges from 5.0 to 6.0 and, wherein the composition comprises no greater than 3% of total impurities as determined by HPLC.Type: ApplicationFiled: September 22, 2020Publication date: March 25, 2021Inventors: Harish Govindaraja Setty CHINNARI, Somashekhar BATTINI, Jagdish Lotan LOHAR